Background: Aripiprazole is a second-generation antipsychotic known for its partial dopamine D2 agonist properties, which help reduce the risk of extrapyramidal symptoms. While effective and generally well-tolerated, withdrawal symptoms, such as Restless Legs Syndrome (RLS) and akathisia, have been observed upon abrupt discontinuation in some patients. Objective: To report a rare case of Restless Legs Syndrome (RLS) following the discontinuation of aripiprazole in a patient with a history of substance-induced psychosis. Case Description: A 39-year-old male with a history of polysubstance use in sustained remission, presented with RLS-like symptoms shortly after discontinuing aripiprazole, which he had taken consistently for the last 6 years. The symptoms, which included a pinching sensation in his thighs, involuntary leg movements during sleep, and a sense of restlessness, emerged within 2 - 3 days of medication cessation. These symptoms are resolved within an hour of reinitiating aripiprazole. The patient’s clinical presentation underscores a rare but clinically significant withdrawal phenomenon associated with aripiprazole discontinuation, potentially linked to dopamine dysregulation. Conclusions: This case highlights the importance of recognizing and managing aripiprazole discontinuation symptoms, including RLS. Clinicians should consider a gradual tapering protocol for aripiprazole to minimize withdrawal-related movement disorders and monitor patients for emergent symptoms. Further research is recommended to establish standardized guidelines for managing similar cases.
Sadock, B.J. Sadock, V.A. and Ruiz, P. (2015) Kaplan & Sadock’s Synopsis of Psychiatry: Behavioral Sciences/Clinical Psychiatry. Wolters Kluwer. https://books.google.com/books/about/Kaplan_Sadock_s_Synopsis_of_Psychiatry.html?id=QQmOngEACAAJ
[3]
Gardos, G., Cole, J.O. and Tarsy, D. (1978) Withdrawal Syndromes Associated with Antipsychotic Drugs. American Journal of Psychiatry, 135, 1321-1324. https://doi.org/10.1176/ajp.135.11.1321
[4]
Trenkwalder, C., Allen, R., Högl, B., Clemens, S., Patton, S., Schormair, B., etal. (2018) Comorbidities, Treatment, and Pathophysiology in Restless Legs Syndrome. The LancetNeurology, 17, 994-1005. https://doi.org/10.1016/s1474-4422(18)30311-9
[5]
Moseley, C.N., Simpson-Khanna, H.A., Catalano, G. and Catalano, M.C. (2013) Covert Dyskinesia Associated with Aripiprazole. ClinicalNeuropharmacology, 36, 128-130. https://doi.org/10.1097/wnf.0b013e31829b99d9
[6]
Taylor, D.M., Barnes, T.R.E. and Young, A.H. (2021) The Maudsley Prescribing Guidelines in Psychiatry. 14th Edition, Wiley-Blackwell. https://doi.org/10.1002/9781119870203
[7]
Stroup, T.S., McEvoy, J.P., Ring, K.D., Hamer, R.H., LaVange, L.M., Swartz, M.S., etal. (2011) A Randomized Trial Examining the Effectiveness of Switching from Olanzapine, Quetiapine, or Risperidone to Aripiprazole to Reduce Metabolic Risk: Comparison of Antipsychotics for Metabolic Problems (CAMP). AmericanJournalofPsychiatry, 168, 947-956. https://doi.org/10.1176/appi.ajp.2011.10111609
[8]
Shapiro, D.A., Renock, S., Arrington, E., Chiodo, L.A., Liu, L., Sibley, D.R., etal. (2003) Aripiprazole, a Novel Atypical Antipsychotic Drug with a Unique and Robust Pharmacology. Neuropsychopharmacology, 28, 1400-1411. https://doi.org/10.1038/sj.npp.1300203
[9]
Shireen, E. (2016) Experimental Treatment of Antipsychotic-Induced Movement Disorders. JournalofExperimentalPharmacology, 8, 1-10. https://doi.org/10.2147/jep.s63553
[10]
de Bartolomeis, A., Tomasetti, C. and Iasevoli, F. (2015) Update on the Mechanism of Action of Aripiprazole: Translational Insights into Antipsychotic Strategies Beyond Dopamine Receptor Antagonism. CNS Drugs, 29, 773-799. https://doi.org/10.1007/s40263-015-0278-3